CORD-19:2008f024274c53b0de1276f4047a6a641813fd98 / 54096-54341 JSONTXT

{"project":"CORD-19-Sentences","denotations":[{"id":"T41878","span":{"begin":0,"end":11},"obj":"Sentence"},{"id":"T20291","span":{"begin":12,"end":245},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Background: Omalizumab, a monoclonal anti-IgE antibody, significantly improves asthma-related quality of life (ARQL) for patients with moderatesevere allergic asthma who express symptoms despite moderate-high inhaled corticosteroids (ICS) doses."}

{"project":"Epistemic_Statements","denotations":[{"id":"T95","span":{"begin":0,"end":245},"obj":"Epistemic_statement"}],"text":"Background: Omalizumab, a monoclonal anti-IgE antibody, significantly improves asthma-related quality of life (ARQL) for patients with moderatesevere allergic asthma who express symptoms despite moderate-high inhaled corticosteroids (ICS) doses."}

{"project":"CORD-19_Custom_license_subset","denotations":[{"id":"T39","span":{"begin":0,"end":11},"obj":"Sentence"},{"id":"T40","span":{"begin":12,"end":245},"obj":"Sentence"}],"text":"Background: Omalizumab, a monoclonal anti-IgE antibody, significantly improves asthma-related quality of life (ARQL) for patients with moderatesevere allergic asthma who express symptoms despite moderate-high inhaled corticosteroids (ICS) doses."}

{"project":"CORD-19-PD-MONDO","denotations":[{"id":"T474","span":{"begin":79,"end":85},"obj":"Disease"},{"id":"T475","span":{"begin":150,"end":165},"obj":"Disease"},{"id":"T476","span":{"begin":150,"end":158},"obj":"Disease"},{"id":"T477","span":{"begin":159,"end":165},"obj":"Disease"},{"id":"T478","span":{"begin":234,"end":237},"obj":"Disease"}],"attributes":[{"id":"A474","pred":"mondo_id","subj":"T474","obj":"http://purl.obolibrary.org/obo/MONDO_0004979"},{"id":"A475","pred":"mondo_id","subj":"T475","obj":"http://purl.obolibrary.org/obo/MONDO_0004784"},{"id":"A476","pred":"mondo_id","subj":"T476","obj":"http://purl.obolibrary.org/obo/MONDO_0004980"},{"id":"A477","pred":"mondo_id","subj":"T477","obj":"http://purl.obolibrary.org/obo/MONDO_0004979"},{"id":"A478","pred":"mondo_id","subj":"T478","obj":"http://purl.obolibrary.org/obo/MONDO_0016575"}],"text":"Background: Omalizumab, a monoclonal anti-IgE antibody, significantly improves asthma-related quality of life (ARQL) for patients with moderatesevere allergic asthma who express symptoms despite moderate-high inhaled corticosteroids (ICS) doses."}

{"project":"CORD-19-PD-HP","denotations":[{"id":"T248","span":{"begin":79,"end":85},"obj":"Phenotype"},{"id":"T249","span":{"begin":159,"end":165},"obj":"Phenotype"}],"attributes":[{"id":"A248","pred":"hp_id","subj":"T248","obj":"http://purl.obolibrary.org/obo/HP_0002099"},{"id":"A249","pred":"hp_id","subj":"T249","obj":"http://purl.obolibrary.org/obo/HP_0002099"}],"text":"Background: Omalizumab, a monoclonal anti-IgE antibody, significantly improves asthma-related quality of life (ARQL) for patients with moderatesevere allergic asthma who express symptoms despite moderate-high inhaled corticosteroids (ICS) doses."}